Sign In
Buy ARCT
$5.76
-0.160 (-2.70%)
At Close: Jul 31, 2026
Arcturus Therapeutics to Attend Upcoming Investor Conferences
04:01pm, Wednesday, 23'rd Jul 2025
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the
Citi adds 'upside 90-day catalyst watch' on Arcturus Therapeutics
06:57am, Tuesday, 01'st Jul 2025
08 Jul 09 Jul
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #Arcturus--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the devel
Wall Street Analysts Think Arcturus Therapeutics (ARCT) Could Surge 371.35%: Read This Before Placing a Bet
10:56am, Tuesday, 03'rd Jun 2025
The mean of analysts' price targets for Arcturus Therapeutics (ARCT) points to a 371.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement
Arcturus Therapeutics to Attend Upcoming Investor Conferences
04:01pm, Thursday, 29'th May 2025
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicine company focused on the d
Wall Street Analysts Believe Arcturus Therapeutics (ARCT) Could Rally 503.6%: Here's is How to Trade
11:00am, Thursday, 15'th May 2025
The consensus price target hints at a 503.6% upside potential for Arcturus Therapeutics (ARCT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ear
Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2025 Earnings Call Transcript
07:40pm, Monday, 12'th May 2025
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT ) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants Neda Safarzadeh - Vice President, Head of Investor Relations, Public Re
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Tops Revenue Estimates
06:10pm, Monday, 12'th May 2025
Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $1.58. This compares to loss of $1 per share a year ago.
Earnings Preview: Arcturus Therapeutics (ARCT) Q1 Earnings Expected to Decline
11:05am, Monday, 05'th May 2025
Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025
04:01pm, Tuesday, 22'nd Apr 2025
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the
Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate
12:50pm, Friday, 11'th Apr 2025
The FDA bestows a Fast Track designation to ARCT's sa-mRNA vaccine candidate, ARCT-2304, for active immunization to prevent pandemic influenza A virus H5N1.
Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2024 Earnings Call Transcript
09:44pm, Thursday, 06'th Mar 2025
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT ) Q4 2024 Earnings Conference Call March 6, 2025 4:30 PM ET Company Participants Neda Safarzadeh - Vice President, Head of Investor Relations Joe Payne
Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates
06:15pm, Thursday, 06'th Mar 2025
Arcturus Therapeutics (ARCT) came out with a quarterly loss of $1.11 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.32 per share a year ago.
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress
04:01pm, Thursday, 06'th Mar 2025
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the
